000169082 001__ 169082
000169082 005__ 20250127124930.0
000169082 0247_ $$2doi$$a10.5061/DRYAD.G3B5272
000169082 0247_ $$2doi$$a10.5061/dryad.g3b5272
000169082 037__ $$aDZNE-2022-01789
000169082 041__ $$aEnglish
000169082 1001_ $$aArnoux, Isabelle$$b0
000169082 245__ $$aDataset: Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease
000169082 260__ $$bDryad$$c2018
000169082 3367_ $$2BibTeX$$aMISC
000169082 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1737978554_6605
000169082 3367_ $$026$$2EndNote$$aChart or Table
000169082 3367_ $$2DataCite$$aDataset
000169082 3367_ $$2ORCID$$aDATA_SET
000169082 3367_ $$2DINI$$aResearchData
000169082 520__ $$aCatching primal functional changes in early, “very far from disease onset” (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex- one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the anti-diabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both, early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.
000169082 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000169082 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000169082 588__ $$aDataset connected to DataCite
000169082 650_7 $$2Other$$acortical microcircuits
000169082 650_7 $$2Other$$aHuntington disease
000169082 650_7 $$2Other$$ain vivo calcium imaging
000169082 650_7 $$2Other$$ametformin
000169082 650_7 $$2Other$$aneuronal hyperactivity
000169082 7001_ $$aWillam, Michael$$b1
000169082 7001_ $$0P:(DE-2719)2690834$$aGriesche, Nadine$$b2$$udzne
000169082 7001_ $$0P:(DE-2719)2812064$$aKrummeich, Jennifer$$b3$$udzne
000169082 7001_ $$aWatari, Hirofumi$$b4
000169082 7001_ $$0P:(DE-2719)2811777$$aOffermann, Nina$$b5$$udzne
000169082 7001_ $$0P:(DE-2719)2662310$$aWeber, Stephanie$$b6$$udzne
000169082 7001_ $$aNarayan Dey, Partha$$b7
000169082 7001_ $$aChen, Chen$$b8
000169082 7001_ $$aMonteiro, Olivia$$b9
000169082 7001_ $$0P:(DE-2719)2809898$$aBuettner, Sven$$b10$$udzne
000169082 7001_ $$0P:(DE-2719)2401927$$aMeyer, Katharina$$b11$$udzne
000169082 7001_ $$0P:(DE-2719)2158358$$aBano, Daniele$$b12$$udzne
000169082 7001_ $$aRadyushkin, Konstantin$$b13
000169082 7001_ $$aLangston, Rosamund$$b14
000169082 7001_ $$0P:(DE-HGF)0$$aLambert, Jeremy J.$$b15
000169082 7001_ $$aWanker, Erich$$b16
000169082 7001_ $$aMethner, Axel$$b17
000169082 7001_ $$0P:(DE-2719)2421562$$aKrauss, Sybille$$b18$$udzne
000169082 7001_ $$aSchweiger, Susann$$b19
000169082 7001_ $$aStroh, Albrecht$$b20
000169082 773__ $$a10.5061/dryad.g3b5272
000169082 909CO $$ooai:pub.dzne.de:169082$$pVDB
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2690834$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000169082 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812064$$aExternal Institute$$b3$$kExtern
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811777$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2662310$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2809898$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2401927$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2158358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000169082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2421562$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000169082 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000169082 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000169082 9141_ $$y2018
000169082 9201_ $$0I:(DE-2719)1011006$$kAG Krauß$$lRegulatory RNA-protein interaction in neurodegenerative diseases$$x0
000169082 9201_ $$0I:(DE-2719)1013003$$kAG Bano$$lAging and Neurodegeneration$$x1
000169082 9201_ $$0I:(DE-2719)1013033$$kAG Capasso$$lImmune Regulation$$x2
000169082 9201_ $$0I:(DE-2719)1040300$$kBiorepository$$lBiorepository$$x3
000169082 980__ $$adataset
000169082 980__ $$aVDB
000169082 980__ $$aI:(DE-2719)1011006
000169082 980__ $$aI:(DE-2719)1013003
000169082 980__ $$aI:(DE-2719)1013033
000169082 980__ $$aI:(DE-2719)1040300
000169082 980__ $$aUNRESTRICTED